Immutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer

Reuters

07/29

<a href="https://laohu8.com/S/PRRUF">Immutep Ltd.</a> Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer

Immutep Limited, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555085384"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555085384\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555085384?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555085384","market":"fut","top_or_hot":-1,"title":"Immutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRRUF\">Immutep Ltd.</a> Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMMP\">Immutep Limited</a>, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-29 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRRUF\">Immutep Ltd.</a> Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMMP\">Immutep Limited</a>, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMM.AU","symbol_name":"IMMUTEP LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL9H063j:1","article_id":"2555085384","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555085384","pubTimestamp":1753755259,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immutep Limited, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004  Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa , with MSD's anti-PD-1 therapy, KEYTRUDA , and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMM.AU":"IMMUTEP LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Immutep Ltd.宣布在2025年世界肺癌大会上展示关键的TACTI-004 III期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":0.9},"content_text":"Immutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer\n    \n\nImmutep Limited, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}